Lack of association between genetic variation in the β3-adrenergic receptor gene and insulin resistance in patients with coronary heart disease

Metabolism: Clinical and Experimental

Volumn 48, Issue 5, 1999, Pages 651-654

  Sheu, Wayne Huey Herng ^a   Lee, Wen Jane ^b   Yao, Ying Erh ^b   Jeng, Chii Yeng ^b   Young, Mason Mao Shin ^b   Chen, Ying Tsung ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ARGININE; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; INSULIN; NITRATE; TRYPTOPHAN;

ADRENERGIC SYSTEM; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN RESPONSE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RECEPTOR GENE;

EID: 0032924206     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90066-5     Document Type: Article

References (37)

1. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
2. Reaven GM: Banting Lecture. Role of insulin resistance in human disease. Diabetes 37:1594-1607, 1988
3. Emorine L, Blin N, Strosberg AD: The human β3-adrenoceptor: The search for a physiological function. Trends Pharmacol Sci 15:3-7, 1994
4. Arch JRS, Kaumann AJ: β3 and atypical β-adrenoceptors. Med Res Rev 13:633-729, 1993
5. Walston J, Silver K, Bogardus C, et al: Time of onset of non-insulin dependent diabetes mellitus in subjects with a mutation in the β3- adrenergic receptor gene. N Engl J Med 333:343-347, 1995
6. Widen E, Lehto M, Kanninen T, et al: Association of a polymorphism in the β3 adrenergic receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 333:348-351, 1995
7. Clement K, Vaisse C, Manning BSJ, et al: A mutation in the β3 adrenergic receptor and increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352-354, 1995
8. Rissanen J, Kuopusjarvi J, Pihlajamaki J, et al: The Trp64Arg polymorphism of the β3 adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome. Diabetes Care 20:1319-1323, 1997
9. Fujusawa T, Ikegami H, Yamato E, et al: Try64Arg mutation of β3-adrenergic receptor in essential hypertension. Insulin resistance and the adrenergic system. Am J Hypertens 10:101-105, 1997
10. Young MH, Jeng C-Y, Sheu WHH, et al: Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 72:458-460, 1993
11. Shinozaki K, Suzuki M, Ikebuchi M, et al: Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 19:1-7, 1996
12. Bressler P, Bailey SR, Matsuda M, et al: Insulin resistance and coronary artery disease. Diabetologia 39:1345-1350, 1996
13. Higashi K, Ishikawa T, Ito T, et al: Association of a genetic variation in the beta-3 adrenergic receptor gene with coronary heart disease among Japanese. Biochem Biophys Res Commun 232:728-730, 1997
14. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959-965, 1993
15. Anderson RL, Hamman RF, Savage PJ, et al: Exploration of simple insulin sensitivity measures derived from the frequently sampled intravenous glucose tolerance (FSIGT) tests. The Insulin Resistance Atherosclerosis Study. Am J Epidemiol 142:724-732, 1995
16. Fishman WH: Beta-adrenergic receptor blockers: Adverse effects and drug interactions. Hypertension 11:21-29, 1988 (suppl 2)
17. Weinberger MH: Diuretics and their side effects: Dilemma in the treatment of hypertension. Hypertension 11:16-20, 1988 (suppl 2)
18. Sones FMJ, Shirey EK: Cine coronary artenography. Mod Concepts Cardiovasc Dis 31:735-738, 1962
19. Judkins MP: Selective coronary arteriography. I. A percutaneous transfemoral technique. Radiology 89:815-824, 1967
20. Kadish AH, Litle RC, Sternberg JC: A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 14:116-131, 1968
21. Hales CN, Randle PJ: Immunoassay of insulin and insulin antibody precipitate. Biochem J 88:137-146, 1963
22. Wahlefeld AW: Triglyceride: Determination after enzymatic hydrolysis, in Bergmeryer HU (ed): Methods of Enzymatic Analysis. New York, NY, Academic, 1974, pp 1831-1835
23. Allain CA, Poon LS, Chan SCG, et al: Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475, 1974
24. Bachorik PS, Albers JJ: Precipitation methods of quantification of lipoprotein. Methods Enzymol 129:78-100, 1986
25. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein in plasma without the use of the preparative ultracentrifuge. Clin Chem 18:449-502, 1972
26. Sheu WHH, Shieh SM, Fuh MMT, et al: Insulin resistance, glucose intolerance and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia. Arterioscler Thromb 13:367-370, 1993
27. Silver K, Walston J, Wang Y, et al: Molecular scanning for mutations in the β3-adrenergic receptor gene in Nauruans with obesity and noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 81:4155-4158, 1996
28. Kadowaki H, Yasuda K, Iwamoto K, et al: A mutation in the β3-adrenergic receptor is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Comm 215:5555-5560, 1995
29. Stronsberg AD: Association of β3-adrenoceptor polymorphism with obesity and diabetes: Current status. Trends Pharmacol Sci 18:449-454, 1997
30. Lonnqvist F, Thorne A, Nilsell K, et al: A pathogenic role of visceral fat β3 adrenoceptors in obesity. J Clin Invest 95:1109-1116, 1995
31. Urhammer SA, Clausen JO, Hansen T, et al: Insulin sensitivity and body weight change in young white carriers of the codon 64 amino acid polymorphism of the beta 3 adrenergic receptor gene. Diabetes 45:1115-1120, 1996
32. Gagnon J, Mauriege P, Roy S, et al: The Trp64Arg mutation of the beta3 adrenergic receptor gene had no effect on obesity phenotypes in the Quebec Family Study and Swedish Obese Subjects cohort. J Clin Invest 98:2086-2093, 1996
33. Li LS, Lonnqvist F, Luthman H, et al: Phenotypic characterization of the Trp64Arg polymorphism in the β3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia 39:857-860, 1996
34. Mauriege P, Bouchard C: Trp64Arg mutation in β3-adrenoceptor gene of doubtful significance for obesity and insulin resistance. Lancet 348:698-699, 1996
35. Ostrowski J, Kjelsberg MA, Caron MG, et al: Mutagenesis of the β2 adrenergic receptor: How structure elucidates function. Annu Rev Pharmacol Toxicol 32:167-183, 1992
36. Candelore MR, Deng L, Tota LM, et al: Pharmacological characterization of a recently described human beta3-adrenergic receptor mutation. Endocrinology 137:2638-2641, 1996
37. Pietri-Rouxel F, Manning B, Gros J, et al: The biochemical effect of the naturally occurring Trp64 → Arg mutation on human beta 3-adrenoceptor activity. Eur J Biochem 247:1174-1179, 1997